Search | IOVS | ARVO Journals

Showing 1 – 20 of 37

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2022

Model development of VEGF challenge in miniature swine

Meredith Weksler; Alan McDougal; Tyler Pegoraro; Stuart Williams; Mitchell A. deLong; Casey Kopczynski; David Hollander; Jeffrey C. White

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1312 – F0146.

ARVO Annual Meeting Abstract June 2022

Dry eye sign, symptom and quality of life improvements associated with administration of AR-15512

David Wirta; Michelle Senchyna; David G. Evans; Eugene B. ` McLaurin; George W Ousler; Amber E. Lewis; David Hollander

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1513 – A0238.

ARVO Annual Meeting Abstract June 2022

ROCK’Sters, a novel compound class combining Rho kinase inhibition with corticosteroid anti-inflammatory activity for the treatment of ocular inflammation

Jill M. Sturdivant; Curtis Kelly; Daphne Clancy; Natalie Girouard; Maria Ina; Qing Wang; D'Quan Cutno; Stuart Williams; Mitchell A. deLong; Casey Kopczynski; David Hollander; Jeffrey C. White

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2111 – F0127.

ARVO Annual Meeting Abstract June 2021

Novel corticosteroid class reduces inflammation and lowers IOP in animal models

Kevin Carbajal; Maria V. Zaretskaia; Cyndi L. Lichorowic; Jill M. Sturdivant; Meredith Weksler; Alan McDougal; Cheng-Wen Lin; Mitchell A. deLong; Casey Kopczynski; David A. Hollander; Jeff White

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1302.

ARVO Annual Meeting Abstract June 2021

Ocular pharmacokinetics of a novel class of corticosteroids with ROCK inhibitory activity and potential for reduced steroid-associated risks

Maria V. Zaretskaia; Kevin Carbajal; Cyndi L. Lichorowic; Jill M. Sturdivant; Monica Germann; Christopher Romeo; Karen Crews; Angie Glendenning; Meredith Weksler; Alan McDougal; Mitchell A. deLong; Cheng-Wen Lin; Casey Kopczynski; David A. Hollander; Jeff White

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1292.

ARVO Annual Meeting Abstract July 2019

Conjunctival Inflammation Measured by Confocal Microscopy to Evaluate New Therapeutic Agents

Paul J Gomes; Matt J Chapin; David A Hollander; Mark B Abelson

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):6708.

ARVO Annual Meeting Abstract July 2019

Quantitation of fibrosis in a rat model of laser-induced CNV

Zsolt Ablonczy; Christopher Schillo; David A Hollander; Andy Whitlock

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):1256.

ARVO Annual Meeting Abstract July 2018

Establishing a Colony of Non-human Primates with Cystoid Macular Edema

Laura Belen; Kortni Violette; Christopher Schillo; Christopher Gallotta; Christian Grant; Leslie Jost; David Hollander; Andy Whitlock

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):391.

ARVO Annual Meeting Abstract July 2018

Evaluation of the Durability of Dry Eye Symptom Relief Following Daily Use of TrueTear™

Jeff Penzner; David Hollander; Gail Torkildsen; Stephanie Baba; Mark Holdbrook; Michelle Senchyna

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):914.

ARVO Annual Meeting Abstract July 2018

A Randomized, Double-Masked, Parallel-Group, Phase 2a Dry Eye Disease Clinical Trial to Evaluate the Safety and Efficacy of Topical Ocular ADX-102, a Novel Aldehyde Sequestering Agent

David Clark; George W Ousler; David Hollander; Todd Brady

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1967.

ARVO Annual Meeting Abstract July 2018

Tablet-Based Reading Tests in Early Dry Age-Related Macular Degeneration

Divya Narayanan; John David Rodriguez; Garrick Wallstrom; Donna L Welch; Keith Jeffrey Lane; Aron Shapiro; David Hollander; Mark B Abelson

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2424.

ARVO Annual Meeting Abstract July 2018

A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel-Group Phase 2b Allergic Conjunctivitis Clinical Trial of Topical Ocular ADX-102, a Novel Aldehyde Sequestering Agent

Paul J Gomes; Todd Brady; David Hollander; David Clark

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):5571.

ARVO Annual Meeting Abstract July 2018

Delay of oscillatory potentials links animal models to diabetes in the human eye

Zsolt Ablonczy; Cristiana Giancarlo; Christopher Schillo; Kortni Violette; Dennis Guberski; Barak Yahalom; Laura Belen; Claire Gelfman; April Hall; David Hollander; Andy Whitlock

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4445.

ARVO Annual Meeting Abstract July 2018

Preclinical Assessment of the Syk Inhibitor PRT2761 for Allergic Conjunctivitis

Andy Whitlock; Laura Belen; Matt J Chapin; Paul J Gomes; Matt Birrell; Anjali Pandey; David Hollander

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):5568.

ARVO Annual Meeting Abstract June 2017

Use of a Computer-based Critical Flicker Fusion Test Discriminates between Young, Old, and Dry AMD Patients

Connie Slocum; Keith Jeffrey Lane; John David Rodriguez; Aron Shapiro; Mark Abelson; David Hollander

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2347.

ARVO Annual Meeting Abstract June 2017

Dynamic Sensitivity of Corneal TRPM8 Receptors to Menthol Instillation in Dry Eye vs Normal Subjects

Peter Corcoran; Michael Watson; George W Ousler; Endri Angjeli; Keith Jeffrey Lane; Mark B Abelson; David A Hollander

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):469.

ARVO Annual Meeting Abstract June 2017

Staining, lid hyperkeratinization and blink rate: Differences between DED and MGD

Blaine Brown; Peter Corcoran; George W Ousler; Keith Jeffrey Lane; David A Hollander

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2245.

ARVO Annual Meeting Abstract June 2017

Evaluation of 0.05% Cyclosporine Ophthalmic Emulsion on Ocular Surface Staining and Visual Function in Subjects Who Experience Discomfort While Engaging in Electronic Visual Tasking

Karl Stonecipher; Gail Torkildsen; Eugene B McLaurin; Linda Villanueva; George W Ousler; David A Hollander

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2661.

ARVO Annual Meeting Abstract June 2017

Effect of Activity on Interblink Interval Assessed with Continual Blink Tracking using the iBlink ® System in Normal Subjects

Zhouxiao Wu; Endri Angjeli; John David Rodriguez; George W Ousler; Keith Jeffrey Lane; David A Hollander

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2672.

ARVO Annual Meeting Abstract June 2017

Photostress Recovery: A comparison of bleaching methods for surrogate maculopathy endpoints

John David Rodriguez; Keith Jeffrey Lane; David A Hollander

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4715.

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Specify Date Range

Model development of VEGF challenge in miniature swine

Dry eye sign, symptom and quality of life improvements associated with administration of AR-15512

ROCK’Sters, a novel compound class combining Rho kinase inhibition with corticosteroid anti-inflammatory activity for the treatment of ocular inflammation

Novel corticosteroid class reduces inflammation and lowers IOP in animal models

Ocular pharmacokinetics of a novel class of corticosteroids with ROCK inhibitory activity and potential for reduced steroid-associated risks

Conjunctival Inflammation Measured by Confocal Microscopy to Evaluate New Therapeutic Agents

Quantitation of fibrosis in a rat model of laser-induced CNV

Establishing a Colony of Non-human Primates with Cystoid Macular Edema

Evaluation of the Durability of Dry Eye Symptom Relief Following Daily Use of TrueTear™

A Randomized, Double-Masked, Parallel-Group, Phase 2a Dry Eye Disease Clinical Trial to Evaluate the Safety and Efficacy of Topical Ocular ADX-102, a Novel Aldehyde Sequestering Agent

Tablet-Based Reading Tests in Early Dry Age-Related Macular Degeneration

A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel-Group Phase 2b Allergic Conjunctivitis Clinical Trial of Topical Ocular ADX-102, a Novel Aldehyde Sequestering Agent

Delay of oscillatory potentials links animal models to diabetes in the human eye

Preclinical Assessment of the Syk Inhibitor PRT2761 for Allergic Conjunctivitis

Use of a Computer-based Critical Flicker Fusion Test Discriminates between Young, Old, and Dry AMD Patients

Dynamic Sensitivity of Corneal TRPM8 Receptors to Menthol Instillation in Dry Eye vs Normal Subjects

Staining, lid hyperkeratinization and blink rate: Differences between DED and MGD

Evaluation of 0.05% Cyclosporine Ophthalmic Emulsion on Ocular Surface Staining and Visual Function in Subjects Who Experience Discomfort While Engaging in Electronic Visual Tasking

Effect of Activity on Interblink Interval Assessed with Continual Blink Tracking using the iBlink ® System in Normal Subjects

Photostress Recovery: A comparison of bleaching methods for surrogate maculopathy endpoints

To View More...

You must be signed into an individual account to use this feature.